<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122026">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514149</url>
  </required_header>
  <id_info>
    <org_study_id>DM200-103</org_study_id>
    <nct_id>NCT01514149</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ConjuChem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ConjuChem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly
      injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin
      monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly
      injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus (T2DM) on metformin
      monotherapy. This study will be a randomized, double-blind comparison of CJC-1134-PC versus
      placebo. Patients taking metformin will continue to take their metformin at the same dose
      for the duration of the study.

      Patients with T2DM, who meet all the inclusion criteria and none of the exclusion criteria,
      will be randomly assigned to a treatment arm. All patients will undergo weekly clinic visits
      to receive 17 weeks of study treatment, including the titration period.

      CJC-1134-PC or placebo treatment will be administered weekly by subcutaneous injection in
      the abdomen to patients in a fasting state. Patients will be closely monitored and evaluated
      for toxicity on an ongoing basis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated hemoglobin change from baseline (CFB) to Week 18</measure>
    <time_frame>CFB to Week 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to hyperglycemia rescue</measure>
    <time_frame>Up to 18 weeks during treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) to Week 18</measure>
    <time_frame>CFB to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting proinsulin, insulin, C-peptide, fructosamine, and glycosylated albumin CFB to Week 18</measure>
    <time_frame>CFB to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid profile (total cholesterol, low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides, very-low density lipoprotein, LDL/HDL ratio) percent CFB to Week 18</measure>
    <time_frame>CFB to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting body weight CFB to Week 18</measure>
    <time_frame>CFB to Week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Type 2 Diabetes Mellitus (T2DM)</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Weekly CJC-1134-PC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Weekly CJC-1134-PC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - Weekly CJC-1134-PC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 - Weekly CJC-1134-PC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 - Weekly Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJC-1134-PC Injection</intervention_name>
    <description>CJC-1134-PC administered weekly by subcutaneous injection</description>
    <arm_group_label>Arm 1 - Weekly CJC-1134-PC</arm_group_label>
    <arm_group_label>Arm 2 - Weekly CJC-1134-PC</arm_group_label>
    <arm_group_label>Arm 3 - Weekly CJC-1134-PC</arm_group_label>
    <arm_group_label>Arm 4 - Weekly CJC-1134-PC</arm_group_label>
    <other_name>metformin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Weekly placebo for CJC-1134-PC Injection</intervention_name>
    <description>Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection</description>
    <arm_group_label>Arm 5 - Weekly Placebo</arm_group_label>
    <other_name>metformin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women 18 to 70 years of age, inclusive

          -  Body mass index of 27 to 45 kg/m2

          -  Diagnosed with T2DM for at least 6 months before screening

          -  Stable daily dose of metformin monotherapy of ≥1000 mg for at least 3 months before
             screening

          -  FPG ≤240 mg/dL at screening

          -  HbA1c ≥7.0% and ≤11% at screening

          -  A 12-lead electrocardiogram recording without clinically significant arrhythmia, left
             bundle-branch block, or corrected QT interval

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Use of a weight control treatment, including over-the-counter medications (includes
             herbal supplements), or a significant change in body weight (at least ±10%) in the 3
             months before screening

          -  Treatment with any oral antidiabetic agent other than metformin within the 3 months
             before screening

          -  Treatment with insulin for longer than 1 week within the 3 months before screening or
             any treatment with insulin within the 2 weeks before screening

          -  Previous treatment with a glucagon-like peptide 1 (GLP-1) analog or other incretin
             therapy

          -  Receipt of any experimental drug in a clinical trial within 30 days before
             administration of study drug or receipt of any investigational antidiabetic product
             within 3 months before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Soon-Shiong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Executive Officer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Henry, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <zip>29687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henrico</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 8, 2012</lastchanged_date>
  <firstreceived_date>October 20, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>T2DM</keyword>
  <keyword>diabetes</keyword>
  <keyword>ConjuChem</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Glucagon-like peptide-1</keyword>
  <keyword>exendin-4</keyword>
  <keyword>modified exendin-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
